ATE71289T1 - Paucilamellare lipidvesikel. - Google Patents

Paucilamellare lipidvesikel.

Info

Publication number
ATE71289T1
ATE71289T1 AT88903062T AT88903062T ATE71289T1 AT E71289 T1 ATE71289 T1 AT E71289T1 AT 88903062 T AT88903062 T AT 88903062T AT 88903062 T AT88903062 T AT 88903062T AT E71289 T1 ATE71289 T1 AT E71289T1
Authority
AT
Austria
Prior art keywords
lipid vesicles
paucilamellar lipid
vesicles
paucilamellar
wax
Prior art date
Application number
AT88903062T
Other languages
English (en)
Inventor
Donald F H Wallach
Original Assignee
Micro Vesicular Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26699867&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE71289(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Micro Vesicular Systems filed Critical Micro Vesicular Systems
Application granted granted Critical
Publication of ATE71289T1 publication Critical patent/ATE71289T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D17/00—Detergent materials or soaps characterised by their shape or physical properties
    • C11D17/0008—Detergent materials or soaps characterised by their shape or physical properties aqueous liquid non soap compositions
    • C11D17/0017—Multi-phase liquid compositions
    • C11D17/0021—Aqueous microemulsions
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D17/00—Detergent materials or soaps characterised by their shape or physical properties
    • C11D17/0008—Detergent materials or soaps characterised by their shape or physical properties aqueous liquid non soap compositions
    • C11D17/0026—Structured liquid compositions, e.g. liquid crystalline phases or network containing non-Newtonian phase
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/10—Insect repellent
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/812—Liposome comprising an antibody, antibody fragment, antigen, or other specific or nonspecific immunoeffector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/829—Liposomes, e.g. encapsulation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S525/00—Synthetic resins or natural rubbers -- part of the class 520 series
    • Y10S525/936—Encapsulated chemical agent
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Fats And Perfumes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Road Signs Or Road Markings (AREA)
  • Cosmetics (AREA)
  • Excavating Of Shafts Or Tunnels (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT88903062T 1987-03-13 1988-03-08 Paucilamellare lipidvesikel. ATE71289T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2552587A 1987-03-13 1987-03-13
US07/157,571 US4911928A (en) 1987-03-13 1988-03-03 Paucilamellar lipid vesicles
PCT/US1988/000723 WO1988006883A1 (en) 1987-03-13 1988-03-08 Paucilamellar lipid vesicles
EP88903062A EP0352282B1 (de) 1987-03-13 1988-03-08 Paucilamellare lipidvesikel

Publications (1)

Publication Number Publication Date
ATE71289T1 true ATE71289T1 (de) 1992-01-15

Family

ID=26699867

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88903062T ATE71289T1 (de) 1987-03-13 1988-03-08 Paucilamellare lipidvesikel.

Country Status (14)

Country Link
US (1) US4911928A (de)
EP (1) EP0352282B1 (de)
JP (1) JP2589173B2 (de)
KR (1) KR960009647B1 (de)
AT (1) ATE71289T1 (de)
AU (1) AU605581B2 (de)
BR (1) BR8807410A (de)
CA (1) CA1289419C (de)
DE (1) DE3867637D1 (de)
DK (1) DK633388D0 (de)
HU (1) HUT53279A (de)
NO (1) NO885032L (de)
NZ (1) NZ223843A (de)
WO (1) WO1988006883A1 (de)

Families Citing this family (279)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474848A (en) * 1987-03-13 1995-12-12 Micro-Pak, Inc. Paucilamellar lipid vesicles
US5219538A (en) * 1987-03-13 1993-06-15 Micro-Pak, Inc. Gas and oxygen carrying lipid vesicles
DE3867635D1 (de) * 1987-03-13 1992-02-20 Micro Vesicular Systems Lipidversikel aus grenzflaechenaktiven stoffen und sterolen.
US5023086A (en) * 1987-03-13 1991-06-11 Micro-Pak, Inc. Encapsulated ionophore growth factors
US5147723A (en) * 1987-07-28 1992-09-15 Micro-Pak, Inc. Paucilamellar lipid vesicles
US5628936A (en) * 1987-03-13 1997-05-13 Micro-Pak, Inc. Hybrid paucilamellar lipid vesicles
US5234767A (en) * 1987-03-13 1993-08-10 Micro-Pak, Inc. Hybrid paucilamellar lipid vesicles
US5811119A (en) * 1987-05-19 1998-09-22 Board Of Regents, The University Of Texas Formulation and use of carotenoids in treatment of cancer
EP0324455A3 (de) * 1988-01-15 1991-03-27 Hans O. Ribi Neue polymerische Immuno-Adjuvans
US5032457A (en) * 1988-03-03 1991-07-16 Micro Vesicular Systems, Inc. Paucilamellar lipid vesicles using charge-localized, single chain, nonphospholipid surfactants
US5104736A (en) * 1988-03-03 1992-04-14 Micro-Pak, Inc. Reinforced paucilamellar lipid vesicles
US4895452A (en) * 1988-03-03 1990-01-23 Micro-Pak, Inc. Method and apparatus for producing lipid vesicles
US5013497A (en) * 1988-03-03 1991-05-07 Micro-Pak, Inc. Method and apparatus for producing lipid vesicles
US5019174A (en) * 1988-03-03 1991-05-28 Micro Vesicular Systems, Inc. Removing oil from surfaces with liposomal cleaner
US5160669A (en) * 1988-03-03 1992-11-03 Micro Vesicular Systems, Inc. Method of making oil filled paucilamellar lipid vesicles
US5019392A (en) * 1988-03-03 1991-05-28 Micro-Pak, Inc. Encapsulation of parasiticides
US4906476A (en) * 1988-12-14 1990-03-06 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs in lungs
US5510117A (en) * 1989-03-09 1996-04-23 Micro-Pak, Inc. Entrapment vehicle and method
GB8906234D0 (en) * 1989-03-17 1989-05-04 Albright & Wilson Agrochemical suspensions
AU6524990A (en) * 1989-09-21 1991-04-18 Micro Vesicular Systems, Inc. Hybrid paucilamellar lipid vesicles
US5227165A (en) * 1989-11-13 1993-07-13 Nova Pharmaceutical Corporation Liposphere delivery systems for local anesthetics
IE904098A1 (en) * 1989-11-13 1991-05-22 Nova Pharm Corp Lipospheres for controlled delivery of substances
US5188837A (en) * 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
FR2657607B1 (fr) * 1990-01-30 1992-04-30 Durand Muriel Procede de protection de la dihydroxyacetone, dihydroxyacetone protegee par ce procede et produit cosmetique contenant une telle dihydroxyacetone protegee.
US5213810A (en) * 1990-03-30 1993-05-25 American Cyanamid Company Stable compositions for parenteral administration and method of making same
US5165994A (en) * 1990-06-05 1992-11-24 University Of Delaware Spontaneous equilbrium surfactant vesicles
CA2046830C (en) 1990-07-19 1999-12-14 Patrick P. Deluca Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
US6165500A (en) * 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
WO1992003123A1 (en) * 1990-08-28 1992-03-05 Liposome Technology, Inc. Liposome alternative bilayer formulations
ES2089226T3 (es) * 1990-09-06 1996-10-01 Johnson & Son Inc S C Procedimiento para estabilizar liposomas y composiciones que los contienen.
US5145604A (en) * 1990-09-19 1992-09-08 S. C. Johnson & Son, Inc. Aqueous emulsion and aerosol delivery system using same
US5091111A (en) * 1990-09-19 1992-02-25 S. C. Johnson & Son, Inc. Aqueous emulsion and aersol delivery system using same
US5256422A (en) * 1991-03-28 1993-10-26 Micro Vesicular Systems, Inc. Lipid vesicle containing water-in-oil emulsions
AU654858B2 (en) * 1991-03-28 1994-11-24 Novavax, Inc. Lipid vesicle containing water-in-oil emulsions
DE4121945C2 (de) * 1991-07-03 1993-11-04 Merz & Co Gmbh & Co Verfahren zur herstellung von stabilen, hydrophilen oder ambiphilen creme-zubereitungen, enthaltend vesikulaere bestandteile, stabile creme-zubereitungen mit vesikulaeren bestandteilen und deren verwendung
US5213805A (en) * 1991-07-25 1993-05-25 Micro Vesicular Systems, Inc. Lipid vesicles having n,n-dimethylamide derivatives as their primary lipid
US5439967A (en) * 1991-09-17 1995-08-08 Micro Vesicular Systems, Inc. Propylene glycol stearate vesicles
US5643600A (en) * 1991-09-17 1997-07-01 Micro-Pak, Inc. Lipid vesicles containing avocado oil unsaponifiables
US5405615A (en) * 1991-09-17 1995-04-11 Micro Vesicular Systems, Inc. Sucrose distearate lipid vesicles
US5260065A (en) * 1991-09-17 1993-11-09 Micro Vesicular Systems, Inc. Blended lipid vesicles
AU5611894A (en) * 1992-12-02 1994-06-22 Micro Vesicular Systems, Inc. Extended duration antacid product
US5393527A (en) * 1993-01-04 1995-02-28 Becton, Dickinson And Company Stabilized microspheres and methods of preparation
CA2153780C (en) * 1993-01-15 2004-04-13 Micro Vesicular Systems, Inc. Method of inhibiting viral reproduction
US5853755A (en) * 1993-07-28 1998-12-29 Pharmaderm Laboratories Ltd. Biphasic multilamellar lipid vesicles
EP0734251B1 (de) 1993-12-17 2009-10-14 Novavax, Inc. Verfahren zur übertragung eines biologisch aktiven materials an eine zelle
WO1995022989A1 (en) * 1994-02-24 1995-08-31 Micro-Pak, Inc. Vaccines containing paucilamellar lipid vesicles as immunological adjuvants
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
US5629021A (en) * 1995-01-31 1997-05-13 Novavax, Inc. Micellar nanoparticles
FR2730928B1 (fr) * 1995-02-23 1997-04-04 Oreal Composition a base de vesicules lipidiques a ph acide et son utilisation en application topique
US5599548A (en) * 1995-05-08 1997-02-04 Elizabeth Arden Co., Division Of Conopco, Inc. Skin care compositions containing fatty acid amides and retinol or retinyl ester
US5954998A (en) * 1995-05-25 1999-09-21 The Clorox Company Liquid peracid precursor colloidal dispersions: oil-core vesicles
US5902604A (en) 1995-06-06 1999-05-11 Board Of Regents, The University Of Texas System Submicron liposome suspensions obtained from preliposome lyophilizates
US5834014A (en) * 1995-10-06 1998-11-10 The Regents Of The University Of Michigan Stimulation of hair follicles
US5874105A (en) * 1996-01-31 1999-02-23 Collaborative Laboratories, Inc. Lipid vesicles formed with alkylammonium fatty acid salts
US6183774B1 (en) 1996-01-31 2001-02-06 Collaborative Laboratories, Inc. Stabilizing vitamin A derivatives by encapsulation in lipid vesicles formed with alkylammonium fatty acid salts
US6071535A (en) * 1996-01-31 2000-06-06 Collaborative Laboratories, Inc. Lipid vesicles formed with alkylammonium fatty acid salts
US5662957A (en) * 1996-05-03 1997-09-02 Novavax, Inc. Oil containing lipid vesicles with marine applications
US5700679A (en) * 1996-06-07 1997-12-23 Novavax, Inc. Lipid vesicles having a bilayer containing a surfactant with anti-viral and spermicidal activity
US5846551A (en) * 1996-06-10 1998-12-08 E-L Management Corp. Water-based makeup compositions and methods for their preparation
US5747051A (en) * 1996-09-27 1998-05-05 Elizabeth Arden Co., Division Of Conopco, Inc. Skin care compositions containing an amide of a hydroxy fatty acid and a retinoid
US5955092A (en) * 1996-09-27 1999-09-21 Elizabeth Arden Co., Division Of Conopco, Inc. Skin care compositions containing an n-substituted fatty acid amide and retinol or retinyl ester
US5935572A (en) * 1997-01-10 1999-08-10 Collaborative Laboratories, Inc. Composition containing protease separate from glycosidase for removing nits in treating lice infestation
US6039960A (en) 1997-05-28 2000-03-21 E-L Management Corp. Water containing wax-based product
IS4518A (is) 1997-07-09 1999-01-10 Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group Nýtt lyfjaform fyrir bóluefni
US5993852A (en) * 1997-08-29 1999-11-30 Pharmaderm Laboratories Ltd. Biphasic lipid vesicle composition for transdermal administration of an immunogen
TW476788B (en) 1998-04-08 2002-02-21 Kimberly Clark Co A cleanser and the making process thereof
GB9824024D0 (en) * 1998-11-03 1998-12-30 Unilever Plc Shampoo compositions
EE200100342A (xx) * 1998-12-23 2002-10-15 Idea Ag Parendatud ravimvorm in vivo mitteinvasiivseks paikseks rakendamiseks
PT1031347E (pt) 1999-01-27 2002-09-30 Idea Ag Transporte/imunizacao transnasal com veiculos muitissimo adaptaveis
SI1031346T1 (en) 1999-01-27 2002-08-31 Idea Ag Noninvasive vaccination through the skin
US6080211A (en) * 1999-02-19 2000-06-27 Igen, Inc. Lipid vesicle-based fuel additives and liquid energy sources containing same
CA2309373A1 (en) * 1999-05-27 2000-11-27 Johnson & Johnson Consumer Companies, Inc. Novel topical formulations
MXPA02000053A (es) * 1999-07-05 2003-07-21 Idea Ag Un metodo para mejorar el tratamiento a traves de barreras adaptables semipermeables.
US6309664B1 (en) 1999-09-15 2001-10-30 Igen, Incorporated Methods, uses and compositions of fluid petrolatum
US6534078B1 (en) * 1999-10-18 2003-03-18 Natural Pest Fx, Inc. Micro-encapsulated pepper-mustard composition and methods of using the same
US6375968B1 (en) 1999-10-22 2002-04-23 3M Innovative Properties Company Encapsulated active material immobilized in hydrogel microbeads
US6376514B1 (en) 2000-10-17 2002-04-23 The Procter & Gamble Co. Substituted six-membered heterocyclic compounds useful for treating multidrug resistance and compositions and methods thereof
US6540991B2 (en) 2001-04-06 2003-04-01 3M Innovative Properties Company Stabilized active materials
US6562361B2 (en) 2001-05-02 2003-05-13 3M Innovative Properties Company Pheromone immobilized in stable hydrogel microbeads
US20030129180A1 (en) * 2001-08-01 2003-07-10 The Proctor & Gamble Company Products and methods for treating microbial infections
EP1423430A1 (de) * 2001-08-16 2004-06-02 Lyfjathroun H.F., Biopharmaceuticals Verfahren zur ex-vivo-herstellung von antikörpern
US6709663B2 (en) 2001-08-31 2004-03-23 Healthpoint, Ltd. Multivesicular emulsion drug delivery systems
EP1304103B1 (de) * 2001-10-22 2008-12-31 Viroblock SA Non-phospholipid Vesikel (npLV) und ihre Verwendung in kosmetischen, therapeutischen und prophylaktischen Anwendungen
US20030129213A1 (en) * 2001-12-26 2003-07-10 Gonzalez Anthony D. Meta-stable insect repellent emulsion composition and method of use
US20030219465A1 (en) * 2002-05-23 2003-11-27 Suresh Kumar Gidwani Composition for delivery of dithranol
US20030232091A1 (en) * 2002-06-17 2003-12-18 Adi Shefer Stabilized retinol for cosmetic dermatological, and pharmaceutical compositions, and use thereof
US7473432B2 (en) * 2002-10-11 2009-01-06 Idea Ag NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
US20040087564A1 (en) * 2002-10-31 2004-05-06 Wright D. Craig Delivery composition and method
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
WO2005030787A2 (en) * 2003-09-29 2005-04-07 Topigen Pharmaceutique Inc. Oligonucleotide compositions and methods for treating disease including inflammatory conditions
CA2563267C (en) 2004-04-05 2011-10-11 Kanagawa University Emulsification dispersants, a method for emulsification and dispersion using the emulsification dispersants, emulsions, and emulsion fuels
US8034796B2 (en) * 2004-04-07 2011-10-11 The University Of Georgia Research Foundation, Inc. Glucosamine and glucosamine/anti-inflammatory mutual prodrugs, compositions, and methods
WO2005116086A2 (en) 2004-04-07 2005-12-08 The University Of Georgia Research Foundation, Inc. Glucosamine and glucosamine/anti-inflammatory mutual prodrugs, compositions, and methods
JP4616602B2 (ja) * 2004-09-16 2011-01-19 大日本塗料株式会社 単分散粒子の製造方法
EP1812075B1 (de) 2004-10-29 2013-12-11 Topigen Pharmaceuticals Inc. Antisense-oligonukleotide zur behandlung von allergien und neoplastischer zellproliferation
JP2008519784A (ja) * 2004-11-12 2008-06-12 イデア アクチェンゲゼルシャフト 皮膚状態の治療における拡張表面凝集体
KR101454286B1 (ko) * 2004-12-22 2014-10-27 닛토덴코 가부시키가이샤 섬유화 억제를 위한 약물 담체 및 약물 담체 키트
US20120269886A1 (en) 2004-12-22 2012-10-25 Nitto Denko Corporation Therapeutic agent for pulmonary fibrosis
JP4533420B2 (ja) * 2004-12-22 2010-09-01 日東電工株式会社 線維化抑制のための薬物担体および薬物担体キット
US20080045575A1 (en) * 2004-12-29 2008-02-21 Van Dyke Thomas E Delivery of H2 Antagonists
EP1852177B1 (de) 2005-01-28 2014-02-26 Japan Science and Technology Agency Molekulares aggregat, das dazu befähigt ist, eine phasenumwandlung durch dehydratisierende kondensation zu durchlaufen, und verfahren zur phasenumwandlung davon
EP1910297B1 (de) 2005-07-11 2016-05-25 Aerie Pharmaceuticals, Inc. Isochinolinverbindungen
CA2624362C (en) 2005-10-03 2015-05-26 Mark A. Pinsky Liposomes comprising collagen and their use in improved skin care
JP5714799B2 (ja) 2005-10-18 2015-05-07 ノババックス インコーポレイテッド 機能的インフルエンザウイルス様粒子（ｖｌｐ）
US9572886B2 (en) 2005-12-22 2017-02-21 Nitto Denko Corporation Agent for treating myelofibrosis
EP2019835A4 (de) * 2006-05-19 2010-08-04 Topigen Pharmaceuticals Inc Die expression von phosphodiesterasen beeinflussende oligonukleotide
CA2652362C (en) * 2006-05-19 2014-10-07 Viroblock S.A. A composition for inactivating an enveloped virus
EP2526948A1 (de) * 2006-09-20 2012-11-28 Aerie Pharmaceuticals, Inc. RHO-Kinase-Hemmer
EP2114349B1 (de) * 2006-12-28 2016-09-14 3M Innovative Properties Company Dentalfüllstoff und verfahren
US8455513B2 (en) * 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
AU2008206087A1 (en) * 2007-01-18 2008-07-24 Mark A. Pinsky Materials and methods for delivering antioxidants into the skin
TWI407971B (zh) 2007-03-30 2013-09-11 Nitto Denko Corp Cancer cells and tumor-related fibroblasts
AU2008268461B2 (en) 2007-06-22 2015-04-09 Children's Medical Center Corporation Methods and uses thereof of prosaposin
FR2917976B1 (fr) * 2007-06-29 2010-05-28 Galderma Sa Composition dermatologique comprenant des vehicules lipidiques de calcitriol, son procede de preparation et son utilisation
ES2542644T3 (es) 2007-07-19 2015-08-07 Novavax, Inc. VLPS quiméricas de la gripe aviar
US20090169615A1 (en) 2007-12-26 2009-07-02 Pinsky Mark A Collagen Formulations for Improved Skin Care
US8455514B2 (en) * 2008-01-17 2013-06-04 Aerie Pharmaceuticals, Inc. 6-and 7-amino isoquinoline compounds and methods for making and using the same
US10251839B2 (en) * 2008-01-22 2019-04-09 Igi Laboratories, Inc. Lipid vesicles derived from olive oil fatty acids
CA2724179A1 (en) 2008-05-15 2009-11-19 Topigen Pharmaceuticals Inc. Oligonucleotides for treating inflammation and neoplastic cell proliferation
ES2499395T3 (es) 2008-05-23 2014-09-29 Siwa Corporation Procedimientos para facilitar la regeneración
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
EP2369923B1 (de) * 2008-11-26 2016-06-22 Viroblock SA Verfahren zur hemmung von gram-positiv-bakterien unter verwendung von nicht-phospholipid-enthaltenden lipid-vesikeln
EP3718566B1 (de) 2008-12-09 2024-06-12 Novavax, Inc. Modifizierte rsv-f-proteine und anwendungsverfahren dafür
EP3053913B1 (de) 2009-05-01 2018-03-07 Aerie Pharmaceuticals, Inc. Hemmer mit doppelmechanismus zur behandlung von erkrankungen
EP2459187B1 (de) 2009-07-29 2021-01-06 Olsen, Elise Zusammensetzungen und verfahren zur hemmung von haarwachstum
US10143652B2 (en) 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
WO2011038073A1 (en) * 2009-09-23 2011-03-31 Formatech, Inc. Methods for the preparation of liposomes comprising docetaxel
EP3925670A1 (de) 2009-12-17 2021-12-22 Children's Medical Center, Corp. Aus saposin-a gewonnene peptide und verwendungen davon
WO2012047629A2 (en) 2010-09-27 2012-04-12 Siwa Corporation Selective removal of age-modified cells for treatment of ather0sclerosis
US9724405B2 (en) 2010-11-05 2017-08-08 Novavax, Inc. Rabies glycoprotein virus-like particles (VLPS)
US8721571B2 (en) 2010-11-22 2014-05-13 Siwa Corporation Selective removal of cells having accumulated agents
JP2014504184A (ja) 2010-12-01 2014-02-20 スパイナル・モデュレーション・インコーポレイテッド 神経構造への薬剤の直接送達
AU2012271413B2 (en) 2011-06-17 2017-07-13 President And Fellows Of Harvard College Frizzled 2 as a target for therapeutic antibodies in the treatment of cancer
AU2012275091B2 (en) 2011-06-29 2017-08-03 Avidas Pharmaceuticals Llc Topical formulations including lipid microcapsule delivery vehicles and their uses
CA2853829C (en) 2011-07-22 2023-09-26 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
AU2012358269B2 (en) 2011-12-22 2017-11-02 Children's Medical Center Corporation Saposin-A derived peptides and uses thereof
WO2013119602A1 (en) 2012-02-06 2013-08-15 President And Fellows Of Harvard College Arrdc1-mediated microvesicles (armms) and uses thereof
AU2013202595B2 (en) 2012-03-30 2016-04-21 Biogen Ma Inc. Methods for modulating Tau expression for reducing seizure and modifying a neurodegenerative syndrome
US9644207B2 (en) 2013-03-14 2017-05-09 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating Tau expression
US10376562B2 (en) 2013-03-15 2019-08-13 The Jackson Laboratory Methods for promoting wound healing and hair growth comprising GDNF administration
CN105263494A (zh) 2013-03-15 2016-01-20 爱瑞制药公司 联合治疗
US20140325490A1 (en) * 2013-04-25 2014-10-30 Hewlett-Packard Development Company, L.P. Classifying Source Code Using an Expertise Model
TWI772856B (zh) 2013-07-19 2022-08-01 美商百健Ｍａ公司 用於調節τ蛋白表現之組合物
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
RU2685185C2 (ru) 2013-09-19 2019-04-16 Новавакс, Инк. Иммуногенные композиции коронавируса ближневосточного респираторного синдрома (mers-cov) и способы
US20150166985A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting von willebrand factor point mutations
ES2780598T3 (es) * 2013-12-23 2020-08-26 Dermopartners Sl Método para preparar liposomas de retinaldehído u otros precursores de ácido retinoico y producto así obtenido
EP3177718B1 (de) 2014-07-30 2022-03-16 President and Fellows of Harvard College Cas9-proteine mit ligandenabhängigen inteinen
AU2015311913B2 (en) 2014-09-03 2019-09-12 Boehringer Ingelheim International Gmbh Compound targeting IL-23A and TNF-alpha and uses thereof
AU2015318036B2 (en) 2014-09-19 2021-07-01 Siwa Corporation Anti-AGE antibodies for treating inflammation and auto-immune disorders
US9816080B2 (en) 2014-10-31 2017-11-14 President And Fellows Of Harvard College Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs)
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
US10487324B2 (en) 2015-02-25 2019-11-26 Washington University Methods to detect motor neuron disease comprising micro-RNAs
MY191081A (en) 2015-07-23 2022-05-30 Boehringer Ingelheim Int Compound targetting il-23a and b-cell activating factor (baff) and uses thereof
CA2996007A1 (en) 2015-09-03 2017-03-09 Novavax, Inc. Vaccine compositions having improved stability and immunogenicity
JP2018535953A (ja) 2015-10-13 2018-12-06 シワ コーポレーション 抗ａｇｅ抗体およびその使用方法
SG10202104041PA (en) 2015-10-23 2021-06-29 Harvard College Nucleobase editors and uses thereof
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
KR102579582B1 (ko) 2015-11-17 2023-09-15 에어리 파마슈티컬즈, 인코포레이티드 키나아제 억제제 및 이의 중간체의 제조 방법
CA3021150C (en) 2016-02-19 2023-02-07 Siwa Corporation Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (age)
US10435682B2 (en) 2016-02-19 2019-10-08 University Of South Florida Arginine deiminase gene therapy for disordered proteins
WO2017181116A1 (en) 2016-04-15 2017-10-19 Siwa Corporation Anti-age antibodies for treating neurodegenerative disorders
AU2017277905B2 (en) 2016-06-08 2022-04-14 Children's Medical Center Corporation Engineered Botulinum neurotoxins
JP2019518763A (ja) 2016-06-23 2019-07-04 シワ コーポレーション 様々な疾患及び障害の治療において使用するためのワクチン
EA201990229A1 (ru) 2016-07-08 2019-06-28 Пол Стенмарк Новый ботулинический нейротоксин и его производные
EP3494215A1 (de) 2016-08-03 2019-06-12 President and Fellows of Harvard College Adenosenukleobaseneditoren und verwendungen davon
CN106268551B (zh) * 2016-08-09 2018-11-20 中国石油大学(华东) 一种具有光捕获功能的多级复合微胶囊的制备方法
CN109804066A (zh) 2016-08-09 2019-05-24 哈佛大学的校长及成员们 可编程cas9-重组酶融合蛋白及其用途
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
CN109640966A (zh) 2016-08-31 2019-04-16 爱瑞制药公司 眼用组合物
JOP20190065A1 (ar) 2016-09-29 2019-03-28 Ionis Pharmaceuticals Inc مركبات وطرق لتقليل التعبير عن tau
EP3518981A4 (de) 2016-10-03 2020-06-10 President and Fellows of Harvard College Abgabe von therapeutischen rnas über arrdc1-vermittelte mikrovesikel
AU2017342543B2 (en) 2016-10-14 2024-06-27 President And Fellows Of Harvard College AAV delivery of nucleobase editors
KR20230125856A (ko) 2016-12-23 2023-08-29 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Pcsk9의 유전자 편집
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
US10961321B1 (en) 2017-01-06 2021-03-30 Siwa Corporation Methods and compositions for treating pain associated with inflammation
US10995151B1 (en) 2017-01-06 2021-05-04 Siwa Corporation Methods and compositions for treating disease-related cachexia
US10925937B1 (en) 2017-01-06 2021-02-23 Siwa Corporation Vaccines for use in treating juvenile disorders associated with inflammation
US10858449B1 (en) 2017-01-06 2020-12-08 Siwa Corporation Methods and compositions for treating osteoarthritis
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
CN110662556A (zh) 2017-03-09 2020-01-07 哈佛大学的校长及成员们 癌症疫苗
KR20190127797A (ko) 2017-03-10 2019-11-13 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 시토신에서 구아닌으로의 염기 편집제
IL269458B2 (en) 2017-03-23 2024-02-01 Harvard College Nucleic base editors that include nucleic acid programmable DNA binding proteins
CA3057872A1 (en) 2017-03-31 2018-10-04 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
CA3059803A1 (en) 2017-04-13 2018-10-18 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody
WO2018209320A1 (en) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
US12083228B2 (en) 2017-07-24 2024-09-10 Novavax, Inc. Methods and compositions for treating respiratory disease
WO2019023680A1 (en) 2017-07-28 2019-01-31 President And Fellows Of Harvard College METHODS AND COMPOSITIONS FOR EVOLUTION OF BASIC EDITORS USING PHAGE-ASSISTED CONTINUOUS EVOLUTION (PACE)
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
EP3687566A2 (de) 2017-09-29 2020-08-05 Children's Medical Center Corporation Neurotoxinähnliches toxin und dessen verwendungen
WO2019079347A1 (en) 2017-10-16 2019-04-25 The Broad Institute, Inc. USES OF BASIC EDITORS ADENOSINE
WO2019113210A1 (en) 2017-12-05 2019-06-13 Anthos Partners, Lp Phosphonium-based ionic drug conjugates
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
US10538553B2 (en) 2018-01-05 2020-01-21 University Of South Florida Compounds for the treatment of neurodegenerative diseases
US20220307001A1 (en) 2018-02-27 2022-09-29 President And Fellows Of Harvard College Evolved cas9 variants and uses thereof
US10507226B1 (en) 2018-05-02 2019-12-17 University Of South Florida N-amino peptide beta-sheet mimics for the treatment of Alzheimer's disease
CN119587720A (zh) 2018-05-11 2025-03-11 比姆医疗股份有限公司 利用可编程碱基编辑器系统编辑单核苷酸多态性的方法
US12157760B2 (en) 2018-05-23 2024-12-03 The Broad Institute, Inc. Base editors and uses thereof
EP3820495A4 (de) 2018-07-09 2022-07-20 The Broad Institute Inc. Rna-programmierbare epigenetische rna-modifikatoren und deren verwendungen
JP2021532114A (ja) 2018-07-23 2021-11-25 シワ コーポレーション 放射線曝露及び化学物質曝露の慢性影響を治療するための方法及び組成物
BR112021001904A2 (pt) 2018-08-03 2021-05-04 Beam Therapeutics Inc. editores de nucleobase multiefetores e métodos de usar os mesmos para modificar uma sequência alvo de ácido nucleico
WO2020051360A1 (en) 2018-09-05 2020-03-12 The Broad Institute, Inc. Base editing for treating hutchinson-gilford progeria syndrome
AU2019337703B2 (en) 2018-09-14 2023-02-02 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
US20220282275A1 (en) 2018-11-15 2022-09-08 The Broad Institute, Inc. G-to-t base editors and uses thereof
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
WO2020181180A1 (en) 2019-03-06 2020-09-10 The Broad Institute, Inc. A:t to c:g base editors and uses thereof
WO2020181202A1 (en) 2019-03-06 2020-09-10 The Broad Institute, Inc. A:t to t:a base editing through adenine deamination and oxidation
WO2020181193A1 (en) 2019-03-06 2020-09-10 The Broad Institute, Inc. T:a to a:t base editing through adenosine methylation
WO2020181195A1 (en) 2019-03-06 2020-09-10 The Broad Institute, Inc. T:a to a:t base editing through adenine excision
WO2020181178A1 (en) 2019-03-06 2020-09-10 The Broad Institute, Inc. T:a to a:t base editing through thymine alkylation
AU2020242032A1 (en) 2019-03-19 2021-10-07 Massachusetts Institute Of Technology Methods and compositions for editing nucleotide sequences
US20220204975A1 (en) 2019-04-12 2022-06-30 President And Fellows Of Harvard College System for genome editing
US12473543B2 (en) 2019-04-17 2025-11-18 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
US20220249697A1 (en) 2019-05-20 2022-08-11 The Broad Institute, Inc. Aav delivery of nucleobase editors
JP7808292B2 (ja) 2019-06-13 2026-01-29 ザ ジェネラル ホスピタル コーポレイション 操作されたヒト内在性ウイルス様粒子および細胞への送達のためのその使用方法
EP4010474A1 (de) 2019-08-08 2022-06-15 The Broad Institute, Inc. Basiseditoren mit diversifiziertem zielbereich
WO2021030666A1 (en) 2019-08-15 2021-02-18 The Broad Institute, Inc. Base editing by transglycosylation
WO2021050512A1 (en) 2019-09-09 2021-03-18 Beam Therapeutics Inc. Novel crispr enzymes, methods, systems and uses thereof
AU2020353149A1 (en) 2019-09-26 2022-04-14 President And Fellows Of Harvard College Minimal arrestin domain containing protein 1 (ARRDC1) constructs
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
WO2021108717A2 (en) 2019-11-26 2021-06-03 The Broad Institute, Inc Systems and methods for evaluating cas9-independent off-target editing of nucleic acids
US20230055682A1 (en) 2019-12-03 2023-02-23 Beam Therapeutics lnc. Synthetic guide rna, compositions, methods, and uses thereof
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
EP4097124A1 (de) 2020-01-28 2022-12-07 The Broad Institute Inc. Baseneditoren, zusammensetzungen und verfahren zur modifizierung des mitochondrialen genoms
US20230235309A1 (en) 2020-02-05 2023-07-27 The Broad Institute, Inc. Adenine base editors and uses thereof
EP4100032B1 (de) 2020-02-05 2025-10-15 The Broad Institute, Inc. Geneditierungsverfahren zur behandlung von spinaler muskelatrophie
EP4143315A1 (de) 2020-04-28 2023-03-08 The Broad Institute Inc. <smallcaps/>?ush2a? ?gezielte basisbearbeitung eines thegens
CA3177449A1 (en) 2020-05-01 2021-11-04 Lewis S. Gruber Methods of treating infections
JP2023525304A (ja) 2020-05-08 2023-06-15 ザ ブロード インスティテュート，インコーポレーテッド 標的二本鎖ヌクレオチド配列の両鎖同時編集のための方法および組成物
MX2023001028A (es) 2020-07-24 2023-04-24 Massachusetts Gen Hospital Particulas similares a virus potenciadas y metodos de uso de las mismas para suministro a celulas.
WO2022093195A1 (en) 2020-10-27 2022-05-05 Siwa Corporation Methods and compositions for treating osteoarthritis using anti-age antibodies or age antigens
EP4237556A2 (de) 2020-10-28 2023-09-06 Children's Medical Center Corporation Verkürztes modifiziertes rekombinantes adamts13 und verwendungen davon
WO2022125776A2 (en) 2020-12-09 2022-06-16 Siwa Corporation Methods and compositions for treating kidney diseases
KR20230158476A (ko) 2021-02-19 2023-11-20 빔 테라퓨틱스, 인크. 유전자 요법을 위한 재조합 광견병 바이러스
EP4314265A2 (de) 2021-03-23 2024-02-07 Beam Therapeutics Inc. Neuartige crispr-enzyme, verfahren, systeme und verwendungen davon
KR20240007651A (ko) 2021-04-16 2024-01-16 빔 테라퓨틱스, 인크. 간세포의 유전적 변형
CA3221008A1 (en) 2021-06-02 2022-12-08 Brian CAFFERTY Circular guide rnas for crispr/cas editing systems
WO2022261509A1 (en) 2021-06-11 2022-12-15 The Broad Institute, Inc. Improved cytosine to guanine base editors
AU2022313315A1 (en) 2021-07-23 2024-02-08 Beam Therapeutics Inc. Guide rnas for crispr/cas editing systems
CA3229602A1 (en) 2021-08-20 2023-02-23 Siwa Corporation Methods and compositions for treating fibrotic diseases
US20230270840A1 (en) 2021-09-08 2023-08-31 Beam Therapeutics Inc. Viral guide rna delivery
WO2023076898A1 (en) 2021-10-25 2023-05-04 The Broad Institute, Inc. Methods and compositions for editing a genome with prime editing and a recombinase
WO2023094435A1 (en) 2021-11-23 2023-06-01 Cellectis Sa New tale protein scaffolds with improved on-target/off-target activity ratios
CA3239498A1 (en) 2021-12-03 2023-06-08 David R. Liu Self-assembling virus-like particles for delivery of prime editors and methods of making and using same
US20250382334A1 (en) 2021-12-03 2025-12-18 The Broad Institute, Inc. Self-assembling virus-like particles for delivery of nucleic acid programmable fusion proteins and methods of making and using same
CN119095968A (zh) 2021-12-17 2024-12-06 比姆医疗股份有限公司 Crispr酶、方法、系统及其用途
EP4504925A1 (de) 2022-04-04 2025-02-12 The Broad Institute, Inc. Cas9-varianten mit nichtkanonischen pam-spezifitäten und verwendungen davon
WO2023196772A1 (en) 2022-04-04 2023-10-12 Beam Therapeutics Inc. Novel rna base editing compositions, systems, methods and uses thereof
WO2023205687A1 (en) 2022-04-20 2023-10-26 The Broad Institute, Inc. Improved prime editing methods and compositions
JP2025515503A (ja) 2022-04-28 2025-05-15 ザ ブロード インスティテュート，インコーポレーテッド 塩基エディタをコードするａａｖベクターおよびその使用
WO2023230613A1 (en) 2022-05-27 2023-11-30 The Broad Institute, Inc. Improved mitochondrial base editors and methods for editing mitochondrial dna
WO2023240137A1 (en) 2022-06-08 2023-12-14 The Board Institute, Inc. Evolved cas14a1 variants, compositions, and methods of making and using same in genome editing
JP2025531669A (ja) 2022-08-16 2025-09-25 ザ ブロード インスティテュート，インコーポレーテッド 進化したシチジンデアミナーゼおよびそれを使用してｄｎａを編集する方法
EP4587560A1 (de) 2022-09-16 2025-07-23 Beam Therapeutics Inc. Grosse serinrekombinasen, systeme und verwendungen davon
WO2024077267A1 (en) 2022-10-07 2024-04-11 The Broad Institute, Inc. Prime editing methods and compositions for treating triplet repeat disorders
WO2024102157A1 (en) 2022-11-09 2024-05-16 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
WO2024138087A2 (en) 2022-12-23 2024-06-27 The Broad Institute, Inc. Methods and compositions for modulating cellular factors to increase prime editing efficiencies
EP4652272A1 (de) 2023-01-18 2025-11-26 The Broad Institute Inc. Prime-editierungsvermitteltes durchlesen von codons mit vorzeitiger terminierung (pert)
WO2024155745A1 (en) 2023-01-18 2024-07-25 The Broad Institute, Inc. Base editing-mediated readthrough of premature termination codons (bert)
EP4662306A2 (de) 2023-02-09 2025-12-17 The Broad Institute Inc. Evolved-rekombinasen zur bearbeitung eines genoms in kombination mit prime-bearbeitung
WO2024206125A1 (en) 2023-03-24 2024-10-03 The Broad Institute, Inc. Use of prime editing for treating sickle cell disease
AU2024275592A1 (en) 2023-05-23 2026-01-15 President And Fellows Of Harvard College Evolved and engineered prime editors with improved editing efficiency
WO2025059202A1 (en) 2023-09-11 2025-03-20 Novavax, Inc. Method for detecting anti-sars-cov-2 spike (s) immunoglobulins
WO2025064678A2 (en) 2023-09-20 2025-03-27 The Broad Institute, Inc. Prime editing-mediated readthrough of frameshift mutations (perf)
WO2025081042A1 (en) 2023-10-12 2025-04-17 Renagade Therapeutics Management Inc. Nickase-retron template-based precision editing system and methods of use
WO2025101668A1 (en) 2023-11-06 2025-05-15 Novavax, Inc. Intranasal immunogenic compositions
WO2025106663A1 (en) 2023-11-15 2025-05-22 Slate Bio, Inc. Interleukin-33 variants, compositions and uses thereof
WO2025106677A1 (en) 2023-11-15 2025-05-22 Slate Bio, Inc. Bifunctional il-2 and il-33 proteins for treating autoimmune disease
WO2025106685A1 (en) 2023-11-15 2025-05-22 Slate Bio, Inc. Interleukin-2 superkine and interleukin-33, compositions and uses thereof
WO2025188687A1 (en) 2024-03-04 2025-09-12 Beam Therapeutics Inc. Stable rna compositions with stem loop, and methods thereof
WO2025259863A1 (en) 2024-06-12 2025-12-18 Orbital Therapeutics, Inc. Thermostable ribonuclease r for circular rna purification
WO2026024856A2 (en) 2024-07-23 2026-01-29 The Broad Institute, Inc. Compositions and methods for production of double-stranded dna in cells for programmable gene integration

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3957971A (en) * 1974-07-29 1976-05-18 Lever Brothers Company Moisturizing units and moisturizing compositions containing the same
FR2408387A2 (fr) * 1975-06-30 1979-06-08 Oreal Compositions a base de dispersions aqueuses de spherules lipidiques
FR2315991A1 (fr) * 1975-06-30 1977-01-28 Oreal Procede de fabrication de dispersions aqueuses de spherules lipidiques et nouvelles compositions correspondantes
GB1578776A (en) * 1976-06-10 1980-11-12 Univ Illinois Hemoglobin liposome and method of making the same
US4217344A (en) * 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4356167A (en) * 1978-01-27 1982-10-26 Sandoz, Inc. Liposome drug delivery systems
FR2416008A1 (fr) * 1978-02-02 1979-08-31 Oreal Lyophilisats de liposomes
US4377567A (en) * 1978-10-02 1983-03-22 The Procter & Gamble Company Lipid membrane drug delivery
US4241046A (en) * 1978-11-30 1980-12-23 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
FR2465780A1 (fr) * 1979-09-18 1981-03-27 Oreal Nouveaux tensio-actifs non ioniques, leur procede de preparation et composition les contenant
EP0032622B1 (de) * 1979-12-20 1985-08-14 Dennis Chapman Polymerisationsfähige Phospholipide und deren Polymere, Verfahren zu deren Herstellung, Verfahren zu deren Verwendung für die Bildung von Überzugschichten auf Substraten und zum Bilden von Liposomen und die daraus entstehenden Liposomzusammensetzungen und Substrate mit Überzugschichten
EP0032578B1 (de) * 1980-01-16 1984-07-25 Hans Georg Prof. Dr. Weder Verfahren und Dialysiereinrichtung zur Herstellung von Bilayer-Vesikeln und Verwendung der Bilayer-Vesikel
DE43327T1 (de) * 1980-07-01 1983-01-05 L'Oreal, 75008 Paris Verfahren zur herstellung stabiler dispersionen in einer waessrigen phase von mindestens einer fluessigen, nicht mit wasser mischbaren phase und die entsprechenden dispersionen.
FR2485921A1 (fr) * 1980-07-01 1982-01-08 Oreal Composition cosmetique a base d'une dispersion aqueuse de spherules lipidiques
US4564599A (en) * 1982-08-23 1986-01-14 The Liposome Company, Inc. Liposome composition for lupus assay
JPS5916534A (ja) * 1982-07-19 1984-01-27 Lion Corp 非イオン性界面活性剤系ベシクル分散液
US4551288A (en) * 1982-08-16 1985-11-05 Sandoz, Inc. Processes for the preparation of liposome drug delivery systems
US4485054A (en) * 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
JPS59106423A (ja) * 1982-12-08 1984-06-20 Hiroshi Kiwada リポソ−ム
FR2543018B1 (fr) * 1983-03-22 1985-07-26 Oreal Procede de preparation de vesicules lipidiques par vaporisation de solvants
JPS6072830A (ja) * 1983-09-29 1985-04-24 Kao Corp ベシクル用組成物
JPS6072831A (ja) * 1983-09-29 1985-04-24 Kao Corp ベシクル用組成物
FR2553002B1 (fr) * 1983-10-06 1992-03-27 Centre Nat Rech Scient Procede perfectionne d'obtention de liposomes unilamellaires de diametres eleves, leur application pharmacologique pour l'encapsulage d'un principe actif en vue de son administration extemporanee et dispositif correspondant
US4692433A (en) * 1983-10-12 1987-09-08 The Regents Of The University Of California Method and composition for regulating serum calcium levels of mammals
US4695554A (en) * 1984-02-14 1987-09-22 Becton Dickinson And Company Sac or liposome containing dye (sulforhodamine) for immunoassay
US4610868A (en) * 1984-03-20 1986-09-09 The Liposome Company, Inc. Lipid matrix carriers for use in drug delivery systems
US4619913A (en) * 1984-05-29 1986-10-28 Matrix Pharmaceuticals, Inc. Treatments employing drug-containing matrices for introduction into cellular lesion areas
FR2571963B1 (fr) * 1984-10-24 1987-07-10 Oreal Composition a usage cosmetique ou pharmaceutique contenant des niosomes et au moins un polyamide hydrosoluble et procede de preparation de cette composition.
JPS61207324A (ja) * 1985-03-11 1986-09-13 Agency Of Ind Science & Technol リポソ−ム

Also Published As

Publication number Publication date
KR890700339A (ko) 1989-04-24
EP0352282A1 (de) 1990-01-31
CA1289419C (en) 1991-09-24
JP2589173B2 (ja) 1997-03-12
AU605581B2 (en) 1991-01-17
AU1541688A (en) 1988-10-10
US4911928A (en) 1990-03-27
WO1988006883A1 (en) 1988-09-22
NZ223843A (en) 1990-04-26
NO885032D0 (no) 1988-11-11
DK633388A (da) 1988-11-11
KR960009647B1 (en) 1996-07-23
HUT53279A (en) 1990-10-28
JPH02502094A (ja) 1990-07-12
NO885032L (no) 1988-11-11
EP0352282B1 (de) 1992-01-08
DK633388D0 (da) 1988-11-11
DE3867637D1 (de) 1992-02-20
BR8807410A (pt) 1990-04-10

Similar Documents

Publication Publication Date Title
ATE71289T1 (de) Paucilamellare lipidvesikel.
DK433484D0 (da) Medikamentholdigt lipidvesikelpraeparat
DE3861772D1 (de) Verfahren fuer die herstellung von stabilen oeligen zusammensetzungen.
NO885605L (no) Fremgangsmaate for fremstilling av smoereolje.
DE3586095D1 (de) Herstellung von lipid-vesikeln.
NO884310L (no) Fremgangsmaate for fremstilling av noeytralt papir.
PT88754A (pt) Method of making three-layer paper
DK164483C (da) Fremgangsmaade til opbevaring af phospholipid liposomer
IT8021372A0 (it) Processo per la preparazione di perossidi alcalini o alcalinoterrosi.
IT8119862A0 (it) Corredo per la misurazione di perossidi lipidici.
ES550447A0 (es) Procedimiento para la fabricacion de un lipido formador de liposoma polimerizable
DK554289A (da) Helium-neonlaser
ES542019A0 (es) Procedimiento para producir una n-acilfenilalanina
ES2014481B3 (es) Procedimiento para la fabricacion de vidrieras laminadas.
DE3886915D1 (de) Raman-hohlraumlaser.
IT1227316B (it) Carda per la produzione di veli di fibre e simili
IT1176953B (it) Procedimento per la produzione di poliesteri aromatici
DE3872874D1 (de) Verfahren zur herstellung von liposomen.
DE3850601D1 (de) Verfahren zur Herstellung von Phospholipidderivate.
IT8867697A0 (it) Procedimento per provocare la rottura di una emulsione
DE69008475D1 (de) Herstellung von Podophyllotoxinen unter Verwendung von Podophyllum.
IT8719363A0 (it) Procedimento per la produzione di calcourea.
ES531129A0 (es) Procedimiento para aislar agentes tensioactivos lipidicos
ES1005242Y (es) Microscopio simplificado
IT8419034A0 (it) Procedimento e dispositivo per preparare le estremita&#39; di formazioni di fibre prima della loro impalmatura.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee